Results for this period
Interim period (second quarter)1 April 2026–30 September 2026Non-consolidated (individual)Japanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ thousand).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Domestic sales of the core BC・ROBO-9000RFID model of blood collection tube preparation equipment and systems increased. Demand for consumables and other products remained solid. The market for specimen testing equipment remained highly competitive both in Japan and overseas, resulting in lower revenue.
No matters to report.
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Non-consolidated (individual) |
| Period Covered | 1 April 2026–30 September 2026 |
| Net Sales | ¥4,453,648 thousand (YoY +8.5%) |
| Operating profit | ¥468,211 thousand (YoY +75.7%) |
| Ordinary income | ¥485,739 thousand (YoY +65.0%) |
| Profit attributable to owners of the parent | ¥321,252 thousand (YoY +58.2%) |
| Equity ratio | End of the current fiscal period 85.4 / End of previous period Not disclosed |
| Total assets | ¥15,491,603 thousand |
| Net assets | ¥13,224,029 thousand |
| Cash flows from operating activities | ¥1,090,548 thousand |
| Cash flows from investing activities | ¥-82,426 thousand |
| Cash flows from financing activities | ¥-1,545,587 thousand |
| Cash and cash equivalents at end of period | ¥8,438,760 thousand |
| Revision to Earnings Forecast | No change |
| Regional sales | ¥1,200,197 thousand (YoY +34.0%), ¥144,147 thousand (YoY -29.2%), ¥132,824 thousand (YoY -18.3%), ¥113,652 thousand (YoY -11.2%), ¥2,459,608 thousand (YoY +4.6%), ¥403,217 thousand (YoY +10.7%) |
| Depreciation and amortization | ¥43,470 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary loss Loss on disposal of non-current assets ¥0 thousand |
| Disclosure regarding the going concern assumption | No matters to report. |
| Factors Behind Changes in Business Performance | Domestic sales of the core BC・ROBO-9000RFID model of blood collection tube preparation equipment and systems increased. Demand for consumables and other products remained solid. The market for specimen testing equipment remained highly competitive both in Japan and overseas, resulting in lower revenue. |
Items this document does not state (17)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Domestic sales of the core BC・ROBO-9000RFID model of blood collection tube preparation equipment and systems increased, while demand for consumables and other products remained solid. Gross profit increased in line with higher revenue, and selling, general and administrative expenses declined slightly year on year.